Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:

3 patent-pending new drug families drawing on novel chemical structures;

75 compounds synthesized with preclinical data demonstrating promising results; and

Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Stock Quote

Press Releases & News

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

June 14, 2021

Read More

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

June 3, 2021

Read More

Mindset Announces Participation at Upcoming Events in June 2021

June 1, 2021

Read More